))
CART therapy moving in a fast-paced market for advanced therapies after collaboration between Kite and Arcellx for multiple myeloma
Manage episode 362433361 series 3473072
المحتوى المقدم من seriously stem cells and Seriously stem cells. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة seriously stem cells and Seriously stem cells أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
In this episode, we're giving audiences an update on the latest news of stem cell technologies. The episode highlights the collaboration between a clinical-stage biotech company, Arcellx, and a biopharmaceutical giant, Kite, a Gilead company, on the CART therapy candidate targeting BCMA antigen on multiple myeloma (MM) known as CART-ddBCMA. The candidate is based on a proprietary platform technology D-Domain of Arcellx that aims to improve the efficiency and effective of CART target recognition. Here is more about the candidate in the episode based on the press conference news of Kite and Arcellx.
10 حلقات
مشاركة
